Albireo to Participate in the H.C. Wainwright Global Investment Conference 2022
Rhea-AI Summary
BOSTON, May 19, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO) announced its participation in the H.C. Wainwright Global Life Science Conference from May 23-26, 2022. CFO Simon Harford will present on May 25, with an on-demand option available on the Albireo Investors page. Additionally, both Simon and Chief Commercial Officer Pamela Stephenson will conduct investor meetings.
Albireo focuses on developing bile acid modulators for rare liver diseases. Its lead product, Bylvay, is FDA-approved for pruritus in progressive familial intrahepatic cholestasis and undergoing trials for other conditions.
Positive
- None.
Negative
- None.
News Market Reaction – ALBO
In the trading session that priced this news, ALBO gained 0.68%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, May 19, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced participation in the H.C. Wainwright Global Life Science Conference May 23-26, 2022. Simon Harford, Chief Financial Officer, will be presenting on Wednesday, May 25, which will be available on-demand on the Albireo Investors page ir.albireopharma.com. Simon and Pamela Stephenson, Chief Commercial Officer, will host meetings with investors.
About Albireo
Albireo Pharma is a rare disease company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases. Albireo’s lead product, Bylvay, was approved by the U.S. FDA as the first drug for the treatment of pruritus in all types of progressive familial intrahepatic cholestasis (PFIC), and it is also being developed to treat other rare pediatric cholestatic liver diseases with Phase 3 trials in Alagille syndrome (ALGS) and biliary atresia, as well as Open-label Extension (OLE) studies for PFIC and ALGS. In Europe, Bylvay has been approved for the treatment of PFIC with pricing listing in Germany and guidance from the National Institute for Health and Care Excellence (NICE) recommending Bylvay for use in the National Health Service in England, Wales and Northern Ireland. The Company has also completed a Phase 1 clinical trial for A3907 to advance development in adult cholestatic liver disease, with IND-enabling studies progressing with A2342 for viral and cholestatic liver disease. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. For more information on Albireo, please visit www.albireopharma.com.
Media Contact:
Colleen Alabiso, 857-356-3905, colleen.alabiso@albireopharma.com
Lance Buckley, 917-439-2241, lbuckley@lippetaylor.com
Investor Contact:
Hans Vitzthum, LifeSci Advisors, LLC., 617-430-7578
